Fertility drug Rekovelle gets reimbursable in combo with hMG

Korea Biomedical Review

10 May 2022 - Ferring’s Rekovelle (follitropin delta), a treatment to promote egg production in ovaries, became reimbursable when used in combination with human menopausal gonadotropin (hMG) in women receiving in vitro fertilization or intracytoplasmic sperm injection.

Ferring Korea said Rekovelle got health insurance benefits in combo with hMG starting from May 1, citing a Health Insurance Review and Assessment Service notice.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Listing , Market access , Korea